세계의 지질조절제 시장 - 유형별, 적응증별, 투여경로별, 유통채널별 예측(2024-2032년)

Lipid regulators market size is anticipated to grow at 3.8% CAGR between 2024 and 2032, driven by the increasing prevalence of cardiovascular diseases, such as heart attacks and strokes, due to factors like unhealthy diets, sedentary lifestyles, and aging populations. As per CDC, every 40 seconds, an individual in the U.S. experiences a heart attack, totaling approximately 805,000 people annually. Lipid regulators are medications that help manage cholesterol levels and reduce the risk of cardiovascular events.

The rising awareness about the importance of lipid management among healthcare professionals and patients has led to increased diagnosis and treatment rates. Moreover, favorable government initiatives aimed at promoting cardiovascular health, such as public health campaigns, screening programs, and reimbursement policies for lipid-regulating medications will play a significant role in driving market growth. These initiatives help raise awareness, improve access to healthcare services, and reduce the economic burden of cardiovascular diseases, further encouraging the adoption of lipid regulators.

The overall market is classified based on type, indication, distribution channel, route of administration and region.

By route of administration, the lipid regulators industry from the injectable segment is anticipated to witness 3.1% CAGR through 2032. Injectable lipid regulators offer a convenient and effective treatment option for patients who may have difficulty adhering to oral therapies or who require rapid and precise control of lipid levels. Additionally, injectable formulations often provide more consistent and predictable absorption, leading to improved therapeutic outcomes and patient compliance.

In terms of distribution channel, the lipid regulators market from the online pharmacies segment will record 4.5% growth rate during 2024 -2032. The convenience and accessibility offered by online pharmacies makes it easier for patients to access lipid-regulating medications, thereby increasing treatment adherence and compliance. Patients can conveniently order their prescriptions online and have them delivered to their doorstep while eliminating the need for frequent visits to traditional brick-and-mortar pharmacies. Additionally, online pharmacies offer competitive pricing and discounts, making lipid regulators more affordable and attractive to patients.

Europe lipid regulators industry will witness rapid expansion at 4.4% CAGR between 2024 and 2032, attributed to the increasing prevalence of cardiovascular diseases and related risk factors, such as obesity and sedentary lifestyles. Stringent healthcare regulations and guidelines emphasizing the importance of cholesterol management are contributing to the need for lipid regulators by promoting early diagnosis and treatment of lipid disorders. Rising advancements in pharmaceutical R&D coupled with the introduction of novel lipid-regulating therapies may further stimulate the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Advancements in drug development
    • 3.2.1.3 Growing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with lipid regulators
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Statins
  • 5.2.1 Branded statins
  • 5.2.2 Statin combination
  • 5.2.3 Generic statins
• 5.3 Non-statins
  • 5.3.1 Fibric-acid derivatives
  • 5.3.2 Bile-acid sequestrants
  • 5.3.3 Ezetimibe
  • 5.3.4 Nicotinic acid derivatives
  • 5.3.5 PCSK9 inhibitors
  • 5.3.6 Other non-statins

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypercholesterolemia
• 6.3 Hypertriglyceridemia
• 6.4 Coronary artery disease
• 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc
• 10.2 Amgen Inc.
• 10.3 AstraZeneca plc
• 10.4 Bristol-Myers Squibb
• 10.5 Dr. Reddy's Laboratories Ltd.
• 10.6 Merck & Co.
• 10.7 Novartis AG
• 10.8 Pfizer, Inc.
• 10.9 Sanofi
• 10.10 Teva Pharmaceuticals